With two large campuses in Berlin, New Jersey, and Marlton, New Jersey (both just 20 minutes from Philadelphia), CenExel HRI, formerly Hassman Research Institute, is a leading clinical research organization that conducts studies in a wide variety of therapeutic areas. CenExel HRI’s highly trained and experienced staff, including four board certified clinical investigators, is dedicated to maintaining the highest standard of quality results in the trials they conduct.
On the CenExel HRI campus there are 14 private practices led by physicians that serve as sub-investigators. Their specialties include psychiatry, addictions, abuse liability, neurology, cardiology, dermatology, ophthalmology, endocrinology, ear, nose and throat (ENT), gastroenterology, orthopedics, pain management, and obstetrics and gynecology (OBGYN). With the help of referrals from the five multi-specialty practices a database of over 80,000 subjects has been developed over the years. CenExel HRI conducts a full complement of inpatient and outpatient Phase I-V research trials and focuses on special populations including the elderly, patients facing addiction, and patients with psychiatric, neurological, and medical disorders. Additional specialized studies include pain models for new compound development, pain management, human abuse liability, hepatic/renal, and several additional therapeutic areas.
Led by Dr. Howard Hassman, CenExel HRI is well-positioned to provide the scientific leadership and operational expertise needed to ensure the success of our clinical research. Our significant experience and proven track-record in managing complex single and multiple ascending trials, including the use of translationally meaningful pharmacodynamics (PD) biomarkers, can de-risk proof of concept studies. In Phase I, these combination trials can allow physicians to identify potential risks and threats to compound viability, as well as help them to implement strategies to overcome these challenges. We take pride not only in our therapeutic experience, but also in our commitment to building long-term partnerships.
CenExel HRI offers
An outstanding team of experts who oversee the setup and conduct of each clinical study. Dr. Howard Hassman has an extensive background in psychodynamic psychotherapy, pain management, psychopharmacology and addiction medicine. As Chief Scientific Officer, Dr. Hassman leads a highly-experienced team of Board Certified Investigators, Psychometric and Pain/Addiction Raters, Clinical Research Coordinators, and Quality Assurance and Regulatory Affairs Specialists. The CenExel HRI team is the backbone of our company and driving force behind meeting critical project deadlines while maintaining the highest standard of quality for pharmaceutical sponsors.